In humans, long-term antipsychotic treatment is known to induce movement disorders and a psychosis, called dopamine supersensitivity psychosis (DSP). The mechanism by which chronic administration of antipsychotic(s) causes DSP may be the treatment-induced up-regulation of dopamine D2 receptors (DRD2). G protein-coupled receptor kinase 6 (GRK6) and beta-arrestin 2 (ARRB2) play important roles in the trafficking of DRD2 by phosphorylation and internalization. We investigated the effects of chronic continuous treatment with mini-pump-administered haloperidol (HAL) on the sensitivity of Wistar rats to dopamine, as measured by the locomotor response to methamphetamine (MAP) and the density of striatal DRD2. Chronic continuous treatment with HAL resulted in significantly higher locomotor response to MAP and significantly higher striatal DRD2 density compared with those in rats administered vehicle (VEH). Enzyme-linked immunosorbent assays revealed that striatal ARRB2 in DSP model rats tended to decrease in comparison with that in the VEH group. In addition, the ratio of GRK6/ARRB2 in DSP model rats was significantly higher than that in controls. Our results suggest that alterations of the GRK6 and ARRB2 system could induce both DRD2 up-regulation and impairment of the dopamine signaling pathway, resulting potentially in the development of DSP.
AhmedMRBerthetABychkovE. (2010) Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson’s disease. Sci Transl Med2: 28ra28.
2.
AhmedMRGurevichVVDalbyKN. (2008) Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther325: 276–283.
3.
AhnSShenoySKWeiH. (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem279: 35518–35525.
4.
AllenJAYostJMSetolaV. (2011) Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A108: 18488–18493.
5.
BeaulieuJMGainetdinovRR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev63: 182–217.
6.
BeaulieuJMSotnikovaTDMarionS. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell122: 261–273.
7.
ChouinardG (1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res5: 21–33.
8.
ChouinardGAnnableLRoss-ChouinardA (1986) Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull22: 891–896.
9.
ChouinardGAnnableLRoss-ChouinardA. (1988) A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. J Clin Psychopharmacol8: 21S–26S.
10.
ChouinardGChouinardVA (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom77: 69–77.
11.
ChouinardGJonesBDAnnableL (1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry135: 1409–1410.
12.
Erdtmann-VourliotisMMayerPAmmonS. (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res95: 129–137.
13.
GainetdinovRRBohnLMSotnikovaTD. (2003) Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron38: 291–303.
14.
GoodmanOBJrKrupnickJGSantiniF. (1996) Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature383: 447–450.
15.
HallRAPremontRTLefkowitzRJ (1999) Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol145: 927–932.
16.
HuangNAseARHebertC. (1997) Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: Homogenate binding and autoradiographic studies. Neurochem Int30: 277–290.
17.
HurleMA (2001) Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem77: 486–492.
18.
IbrahimIAAEHKuroseH (2012) β-Arrestin-mediated signaling improves the efficacy of therapeutics. J Pharmacol Sci118:408–412.
19.
InoueAMikiSSetoM. (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol321: 105–111.
20.
IyoMTadokoroSKanaharaN. (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol33: 398–404.
21.
KaneJM (2007) Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry68(Suppl 14): 27–30.
22.
KapurSVanderspekSCBrownleeBA. (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther305: 625–631.
23.
KimuraHKanaharaNKomatsuN. (2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res155: 52–58.
24.
KoFTallericoTSeemanP (2006) Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. Synapse60: 141–151.
25.
KohlerUSchroderHAugustinW. (1994) A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci Lett170: 99–102.
26.
LefkowitzRJShenoySK (2005) Transduction of receptor signals by beta-arrestins. Science308: 512–517.
27.
ManagoFEspinozaSSalahpourA. (2012) The role of GRK6 in animal models of Parkinson’s Disease and L-DOPA treatment. Sci Rep2: 301.
MoncrieffJ (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand114: 3–13.
30.
PitcherJAFreedmanNJLefkowitzRJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem67: 653–692.
31.
RaehalKMSchmidCLMedvedevIO. (2009) Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend104: 187–196.
32.
RibasCPenelaPMurgaC. (2007) The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta1768: 913–922.
33.
SamahaANSeemanPStewartJ. (2007) “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci27: 2979–2986.
34.
SchmidCLBohnLM (2009) Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther121: 285–293.
35.
SeemanP (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther17: 118–132.
36.
SeemanP (2013a) Are dopamine D2 receptors out of control in psychosis?Prog Neuropsychopharmacol Biol Psychiatry46: 146–152.
37.
SeemanP (2013b) Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol23: 999–1009.
SeemanPUlpianCBergeronC. (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science225: 728–731.
40.
SilvestriSSeemanMVNegreteJC. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl)152: 174–180.
41.
TadokoroSOkamuraNSekineY. (2011) Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull38: 1012–1020.
42.
WatariKNakayaMKuroseH (2014) Multiple functions of G protein-coupled receptor kinases. J Mol Signal9: 1.
43.
WhalenEJRajagopalSLefkowitzRJ (2011) Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med17: 126–139.
